| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.
|
Ann Med
|
2010
|
4.14
|
|
2
|
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.
|
Hepatology
|
2002
|
3.29
|
|
3
|
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD).
|
Prog Lipid Res
|
2008
|
2.77
|
|
4
|
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.
|
Hepatology
|
2010
|
2.67
|
|
5
|
Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes.
|
Annu Rev Med
|
2011
|
2.59
|
|
6
|
Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis.
|
Hepatology
|
2003
|
2.44
|
|
7
|
Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?
|
Diabetes Care
|
2010
|
2.22
|
|
8
|
Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.
|
Diabetes Care
|
2007
|
2.02
|
|
9
|
A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
|
Ann Med
|
2011
|
2.01
|
|
10
|
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C.
|
Hepatology
|
2009
|
1.71
|
|
11
|
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
|
Am J Gastroenterol
|
2008
|
1.69
|
|
12
|
High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study.
|
J Hypertens
|
2009
|
1.49
|
|
13
|
Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders.
|
Curr Opin Lipidol
|
2010
|
1.42
|
|
14
|
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease.
|
Hepatology
|
2005
|
1.34
|
|
15
|
Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis.
|
Am J Gastroenterol
|
2005
|
1.27
|
|
16
|
Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes.
|
Diabetes
|
2009
|
1.25
|
|
17
|
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy.
|
Diabetes
|
2010
|
1.21
|
|
18
|
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis.
|
Prog Lipid Res
|
2012
|
1.20
|
|
19
|
p53 Mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes.
|
J Biol Chem
|
2005
|
1.12
|
|
20
|
Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver.
|
Am J Clin Nutr
|
2009
|
1.11
|
|
21
|
Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH.
|
Hepatology
|
2008
|
1.09
|
|
22
|
Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.
|
Diabetes
|
2011
|
1.08
|
|
23
|
Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
|
Hepatology
|
2012
|
1.07
|
|
24
|
Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: a possible implication for oxidative stress.
|
World J Gastroenterol
|
2005
|
1.05
|
|
25
|
Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH.
|
Hepatology
|
2009
|
1.02
|
|
26
|
Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: emerging evidence and mechanisms.
|
Semin Liver Dis
|
2012
|
1.00
|
|
27
|
Iron supplementation and gestational diabetes in midpregnancy.
|
Am J Obstet Gynecol
|
2009
|
0.97
|
|
28
|
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver.
|
Trends Mol Med
|
2013
|
0.96
|
|
29
|
Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation.
|
Hepatology
|
2010
|
0.93
|
|
30
|
Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort.
|
Am J Clin Nutr
|
2012
|
0.92
|
|
31
|
Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism.
|
Am J Clin Nutr
|
2013
|
0.91
|
|
32
|
Associations of dietary and serum copper with inflammation, oxidative stress, and metabolic variables in adults.
|
J Nutr
|
2008
|
0.91
|
|
33
|
Emerging molecular targets for the treatment of nonalcoholic fatty liver disease.
|
Annu Rev Med
|
2010
|
0.90
|
|
34
|
STAT5 activation induced by diabetic LDL depends on LDL glycation and occurs via src kinase activity.
|
Diabetes
|
2002
|
0.90
|
|
35
|
RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy.
|
FASEB J
|
2004
|
0.89
|
|
36
|
Mild gestational hyperglycemia, the metabolic syndrome and adverse neonatal outcomes.
|
Acta Obstet Gynecol Scand
|
2004
|
0.86
|
|
37
|
Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism.
|
Diabetes
|
2012
|
0.86
|
|
38
|
Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake.
|
Am J Clin Nutr
|
2007
|
0.86
|
|
39
|
Effects of TCF7L2 polymorphisms on glucose values after a lifestyle intervention.
|
Am J Clin Nutr
|
2009
|
0.86
|
|
40
|
Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease.
|
Hepatology
|
2012
|
0.85
|
|
41
|
Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C.
|
Clin Gastroenterol Hepatol
|
2012
|
0.85
|
|
42
|
Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update.
|
Curr Opin Lipidol
|
2011
|
0.84
|
|
43
|
Cloning and expression of a type IX-like collagen in tissues of the ascidian Ciona intestinalis.
|
Biochim Biophys Acta
|
2002
|
0.82
|
|
44
|
Oxidative stress-mediated mesangial cell proliferation requires RAC-1/reactive oxygen species production and beta4 integrin expression.
|
J Biol Chem
|
2007
|
0.82
|
|
45
|
Efficacy of antioxidant treatment in reducing resistin serum levels: a randomized study.
|
PLoS Clin Trials
|
2007
|
0.82
|
|
46
|
Diabetic LDL inhibits cell-cycle progression via STAT5B and p21(waf).
|
J Clin Invest
|
2002
|
0.82
|
|
47
|
Diet or exercise: what is more effective in preventing or reducing metabolic alterations?
|
Eur J Endocrinol
|
2008
|
0.82
|
|
48
|
Uncoupling protein 2 G(-866)A polymorphism: a new gene polymorphism associated with C-reactive protein in type 2 diabetic patients.
|
Cardiovasc Diabetol
|
2010
|
0.81
|
|
49
|
Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis.
|
J Nutr Biochem
|
2009
|
0.81
|
|
50
|
Mild gestational hyperglycemia and the metabolic syndrome in later life.
|
Metab Syndr Relat Disord
|
2006
|
0.81
|
|
51
|
Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression?
|
J Gastroenterol
|
2009
|
0.80
|
|
52
|
Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH.
|
Hepatology
|
2006
|
0.79
|
|
53
|
Probiotics, prebiotics, energy balance, and obesity: mechanistic insights and therapeutic implications.
|
Gastroenterol Clin North Am
|
2012
|
0.79
|
|
54
|
Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis.
|
Am J Clin Nutr
|
2011
|
0.79
|
|
55
|
Phytosterol-enriched yogurt increases LDL affinity and reduces CD36 expression in polygenic hypercholesterolemia.
|
Lipids
|
2008
|
0.76
|
|
56
|
Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis.
|
Ann Med
|
2008
|
0.76
|
|
57
|
Magnesium intake, glucose and insulin serum levels in pre-school very-low-birth weight pre-term children.
|
Nutr Metab Cardiovasc Dis
|
2006
|
0.76
|
|
58
|
Need for a three-focused approach to nonalcoholic fatty liver disease.
|
Hepatology
|
2011
|
0.75
|
|
59
|
Influence of cyclosporine on low-density lipoprotein uptake in human lymphocytes.
|
Metabolism
|
2005
|
0.75
|
|
60
|
Lipoprotein-apolipoprotein changes in renal transplant recipients.
|
Lipids
|
2002
|
0.75
|
|
61
|
LDL electronegativity is enhanced in type 1 diabetes.
|
Diabetes Care
|
2003
|
0.75
|